The big Covid-19 trials still to report
New findings for IL-6 blockade in the Recovery trial finally confirm a signal. Can pending pandemic readouts for other mechanisms do the same?
Mid-stage angioedema hit sends Kalvista though the roof
The first oral rescue therapy for acute attacks is on the horizon.
World Lung 2020 – amivantamab puts more data behind the hype
But how will the complex J&J bispecific antibody fare in a market where oral small molecules are the norm?
Uniqure’s safety scare shakes haemophilia gene therapy
The whole haemophilia gene therapy field will be hoping that a case of liver cancer in etranacogene dezaparvovec’s pivotal trial is not treatment related.
First-quarter catalysts for the smaller players
Important data releases are on the cards for Rhythm, Wave and Supernus, among others.
Alexion ticks Astra’s boxes
The deal solves several problems for Astra, and ranks as biopharma’s fifth-biggest cross-border transaction.
Incyte’s Jakafi disappoints in severe Covid-19
As Jak inhibition takes a big knock, attention turns to other immunosuppressive mechanisms being studied in very ill Covid-19 patients.
